A case-based clinical report describes lettermovir shielding a rare immunodeficiency patient through a multi-transplant and infection-heavy course. Published in Annals of Hematology, the report follows a 19-year-old with X-linked hyper-IgM syndrome who underwent two organ transplants and multiple opportunistic infections, then emerged three years later with a rebuilt immune system. While case reports do not replace controlled trials, they help map feasibility and safety of antiviral support strategies in complex transplant settings where immune recovery is fragile. The emphasis on prevention and supportive pharmacology is especially relevant for rare immune disorders where outcomes depend on timing, prophylaxis, and infection surveillance. For clinicians and biotech teams, the story reinforces the value of targeted supportive interventions in rare disease care pathways, particularly during high-risk windows after transplantation.